Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vacuum Cleaners That Are Not difficult To Use For Home - 2Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- 3France will build a new aircraft carrier as it increases defense spending
- 4The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
- 5Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Bad flu season getting worse; skyrocketing cases set state record
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- Nations for Rock Climbing
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- Israeli strike on Gaza City vehicle kills at least four, report says
- Which Diet Prompts the Incomparable Wellbeing Results?
